Results

1–4 of 4 results for tolerability

ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
Daniel Su, MD
Annual Meeting Talks
2023
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021